Dr. Avery C. Wright, D.O.
Pediatric Hematology & Oncology (Pediatric Hematology & Oncology Physician)
At a glance
- In the NPI registry since
- 2012
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Hematology & Oncology Physician primary
FL license OS16351
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 4 companies reported 7 payments worth $311 in total to this clinician.
| Day One Biopharmaceuticals | $176 |
|---|---|
| Rhythm Pharmaceuticals, Inc. | $59.50 |
| Springworks Therapeutics, Inc. | $45.59 |
| Jazz Pharmaceuticals Inc. | $29.82 |
| Food and Beverage | $252 |
|---|---|
| Education | $59.50 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Rhythm Pharmaceuticals, Inc. Jun 6, 2025 | Education in-kind | $59.50 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $39,584 in research payments for these studies, mostly to the institutions running them.
- DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
Day One Biopharmaceuticals · Active, not recruiting · NCT05566795 - MEK-NF-201
Springworks Therapeutics, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.